American Capital Advisory’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$18.1K Buy
269
+2
+0.7% +$133 0.01% 310
2026
Q1
$16.8K Buy
267
+4
+2% +$279 0.01% 305
2025
Q4
$17.5K Buy
263
+4
+2% +$259 0.01% 292
2025
Q3
$17.4K Sell
259
-1
-0.4% -$79 0.01% 277
2025
Q2
$22.7K Buy
260
+10
+4% +$784 0.01% 254
2025
Q1
$17.1K Hold
250
0.01% 272
2024
Q4
$19.4K Buy
+250
New +$18.5K 0.01% 253
2024
Q3
Sell
-190
Closed -$23.6K 489
2024
Q2
$23.6K Buy
+190
New +$24K 0.02% 207
2024
Q1
Sell
-190
Closed -$23.6K 476
2023
Q4
$23.6K Buy
+190
New +$19.4K 0.02% 207

Other funds holding DXCM

American Capital Advisory's DXCM Position: Q2 2026 in Review

American Capital Advisory increased its DexCom (DXCM) stake by 0.75% in Q2 2026, buying an estimated $133 and bringing the position to 269 shares worth $18.1K. The position accounts for 0.01% of the portfolio, ranked #310.

American Capital Advisory first reported a position in DXCM in Q4 2023 and has held it in 9 quarters since. The position peaked at $23.6K in Q2 2024. 327 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • American Capital Advisory held 269 shares of DexCom worth $18.1K as of Q2 2026.
  • American Capital Advisory bought 2 DexCom shares in Q2 2026, an estimated $133.
  • DexCom made up 0.01% of American Capital Advisory's portfolio in Q2 2026, its #310 holding.
  • American Capital Advisory first reported a position in DexCom in Q4 2023 and has held it in 9 quarters since.
  • American Capital Advisory's DexCom position peaked at $23.6K in Q2 2024.
  • 327 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.